CARDIOVASCULAR DISEASE

SGLT-2 inhibitors in heart failure: a new therapeutic avenue

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: A timeline of the discovery and evaluation of SGLT2 inhibitors.

References

  1. 1.

    White, J. R. Clin. Diabetes 28, 5–10 (2010).

    Article  Google Scholar 

  2. 2.

    Greene, S. J. et al. J Am Coll Cardiol 71, 1379–1390 (2018).

    Article  Google Scholar 

  3. 3.

    Zelniker, T. A. et al. Lancet 393, 31–39 (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Neuen, B. L. et al. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30256-6 (2019).

    Article  PubMed  Google Scholar 

  5. 5.

    Verma, S. & McMurray, J. J. V. Circulation 139, 2537–2541 (2019).

    Article  Google Scholar 

  6. 6.

    McMurray, J. J. V. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911303 (2019).

    Article  PubMed  Google Scholar 

  7. 7.

    Inzucchi, S. E. et al. Diabetes Care 41, 356–363 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Vijayakumar, S., Vaduganathan, M. & Butler, J. Circulation 137, 1060–1073 (2018).

    Article  Google Scholar 

  9. 9.

    Greene, S. J. et al. J. Am. Coll. Cardiol. 72, 351–366 (2018).

    Article  Google Scholar 

  10. 10.

    Greene, S. J. et al. J. Am. Coll. Cardiol. 73, 2365–2383 (2019).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Javed Butler.

Ethics declarations

Competing interests

M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim and Relypsa, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH. J.B. has served as a consultant to Abbott, Amgen, Array, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharma, Gilead, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, V-Wave Limited and Vifor.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vaduganathan, M., Butler, J. SGLT-2 inhibitors in heart failure: a new therapeutic avenue. Nat Med 25, 1653–1654 (2019). https://doi.org/10.1038/s41591-019-0647-4

Download citation